ClinicalTrials.gg
CompletedNCT03657355Updated Sep 19, 2019

Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users

A Phase 1 interventional study of ACT-541468 and Suvorexant in Healthy Recreational Drug Users, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-19.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2019, 7 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This placebo- and active controlled study will investigate the abuse potential of ACT-541468 in healthy recreational drug users

02

Conditions studied

  • Healthy Recreational Drug Users
03

In context

Lead sponsor

Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed prior to any study-mandated procedure
  • Male or female healthy subjects, 18-55 years of age (inclusive) at Screening
  • of 18.0-33.0 kg/m2 (inclusive) at Screening and a minimum weight of 50.0 kg at Screening
  • Current sedative users who have used sedatives (e.g., benzodiazepines, zolpidem, eszopiclone, gamma-hydroxybutyrate, barbiturates) for recreational (non-therapeutic) purposes (i.e., for psychoactive effects) at least ten times in their life and at least once in the 12 weeks before Screening
  • Women of must consistently and correctly use a reliable method of with a failure rate of \< 1% per year, be sexually inactive, or have a vasectomized partner
  • Women of non-childbearing potential
  • Male subjects are required to use a medically acceptable method of contraception throughout the entire study period and for at least 90 days after last study drug administration

Exclusion criteria

Exclusion Criteria:

  • History of major medical or surgical disorders which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatment(s)
  • Positive or /C test at Screening
  • Female subjects who are currently pregnant or lactating or who are planning to become pregnant within 1 month of the last study treatment administration
  • Modified Swiss Narcolepsy Scale total score \< 0 at Screening or history of narcolepsy or cataplexy
  • Substance or alcohol dependence within 2 years prior to Screening or prior participation in a substance or alcohol dependence rehabilitation program
  • Subjects who have a positive urine drug screen at admittance to the qualification or core phase
  • Any sleep-disorder including self-reported insomnia disorder, breathing-related sleep disorders, restless legs syndrome (RLS), nightmare disorder, non-rapid eye movement (REM), sleep arousal disorders, REM sleep behavior disorder, circadian rhythm sleep-wake disorders, or narcolepsy
  • Any of the following SLEEP-50 Questionnaire scores at Screening:

    • ≥ 15 on Apnea subscale;
    • ≥ 7 on Narcolepsy subscale;
    • ≥ 7 on RLS or Periodic limb movement disorder subscale;
    • ≥ 8 on Circadian Rhythm subscale;
    • ≥ 7 on Sleepwalking subscale;
    • ≥ 3 on Item 32 and ≥ 9 on Items 33 to 35 (i.e., on nightmare subscale);
    • ≥ 15 on Impact subscale.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    50 mg ACT-541468

    ACT-541468 will be administered as tablets for oral use.

    Drug: ACT-541468

  • Experimental
    100 mg ACT-541468

    ACT-541468 will be administered as tablets for oral use.

    Drug: ACT-541468

  • Experimental
    150 mg ACT-541468

    ACT-541468 will be administered as tablets for oral use.

    Drug: ACT-541468

  • Active comparator
    150 mg suvorexant

    Suvorexant will be administered as tablets for oral use.

    Drug: Suvorexant

  • Active comparator
    30 mg zolpidem

    Zolpidem will be administered as tablets for oral use.

    Drug: Zolpidem

  • Placebo comparator
    Placebo

    Placebo will be administered as tablets for oral use.

    Drug: Placebo

Interventions

  • ACT-541468 will be administered as 50 mg tablets for oral use.

  • Suvorexant will be administered as 15 mg over-encapsulated tablets for oral use.

  • Zolpidem will be administered as 10 mg over-encapsulated tablets for oral use.

  • DrugPlacebo

    Matching-placebo will be used.

06

What researchers measure

Primary outcomes

  1. Maximum effect (Emax) of the Drug Liking VAS ('at this moment') over 24 h post-dose during each treatment period

    VAS = visual analogue scale

    Time frame: Duration: for up to 24 hours post-dose

Secondary outcomes

  1. Drug Liking VAS (bipolar)

    VAS = visual analogue scale

    Time frame: Duration: for up to 24 hours post-dose

  2. Overall Drug Liking VAS (bipolar)

    VAS = visual analogue scale

    Time frame: Duration: for up to 12 hours post-dose

  3. Take Drug Again VAS (bipolar)

    Time frame: Duration: for up to 12 hours post-dose

  4. Good Effects VAS (unipolar)

    Time frame: Duration: for up to 24 hours post-dose

  5. Drug Similarity VAS

    VAS = visual analogue scale

    Time frame: Duration: for up to 1 hour post-dose

  6. Bad Effects VAS (unipolar)

    VAS = visual analogue scale

    Time frame: Duration: for up to 24 hours post-dose

  7. Alertness/Drowsiness VAS (bipolar)

    VAS = visual analogue scale

    Time frame: Duration: for up to 24 hours post-dose

  8. Any Effects VAS (unipolar)

    VAS = visual analogue scale

    Time frame: Duration: for up to 24 hours post-dose

  9. Feeling High VAS (unipolar)

    VAS = visual analogue scale

    Time frame: Duration: for up to 24 hours post-dose

  10. Bowdle VAS Internal and External Perceptions

    Time frame: Duration: for up to 24 hours post-dose

  11. Observer's Assessment of Alertness/Sedation composite and sum scores

    Time frame: Duration: for up to 24 hours post-dose

  12. Reaction time task score

    Time frame: Duration: for up to 8 hours post-dose

  13. Rapid visual information processing score

    Time frame: Duration: for up to 8 hours post-dose

  14. Paired Associates Learning score

    Time frame: Duration: for up to 8 hours post-dose

Other outcomes

  1. AUC(0-t) of ACT-541468

    Time frame: Duration: for up to 24 hours post-dose

  2. AUC(0-∞) of ACT-541468

    Time frame: Duration: for up to 24 hours post-dose

  3. Cmax of ACT-541468

    Time frame: Duration: for up to 24 hours post-dose

  4. tmax of ACT-541468

    Time frame: Duration: for up to 24 hours post-dose

  5. t½ of ACT-541468

    Time frame: Duration: for up to 24 hours post-dose

  6. Treatment-emergent adverse events (AEs)

    Time frame: All AEs from (first) admittance on Day -1 up to EOS, i.e. for up to 9 weeks

  7. Treatment-emergent serious AEs (SAEs)

    Time frame: SAE reporting: from signature of informed consent up to EOS, i.e. for up to 13 weeks

07

Study locations

2 sites
  • Altasciences Clinical Kansas, Inc. (former Vince and Associates Clinical Research, Inc.)
    Overland Park, Kansas 66212, United States
  • Altasciences Company Inc.
    Montreal, H3P 3P1, Canada
08

References and documents

Publications

  • Ufer M, Kelsh D, Schoedel KA, Dingemanse J. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem. Sleep. 2022 Mar 14;45(3):zsab224. doi: 10.1093/sleep/zsab224. PubMed 34480579 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Aug 2019, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2018
First posted
Sep 5, 2018
StartActual
Sep 7, 2018
Primary completionActual
Aug 8, 2019
CompletionActual
Aug 8, 2019
Last update
Sep 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03657355
Responsible party
Sponsor
First posted
Sep 5, 2018
Start date
Sep 7, 2018
Primary completion
Aug 8, 2019
Completion
Aug 8, 2019
Last update
Sep 19, 2019

Study contacts

Clinical Trials
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daridorexant

Start the discussion